URACTONUM

This brand name is authorized in Cyprus, Hong Kong SAR China, Malta, Singapore.

Active ingredients

The drug URACTONUM contains one active pharmaceutical ingredient (API):

1	Spironolactone UNII 27O7W4T232 - SPIRONOLACTONE
	Spironolactone, as a competitive aldosterone antagonist, increases sodium excretion whilst reducing potassium loss at the distal renal tubule. It has a gradual and prolonged action.
	Read more about Spironolactone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
URACTONUM Tablet	MPI, EU: SmPC	Υπουργείο Υγείας (CY)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C03DA01	Spironolactone	C Cardiovascular system → C03 Diuretics → C03D Potassium-sparing agents → C03DA Aldosterone antagonists
Discover more medicines within C03DA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
HK	Department of Health Drug Office	23093
MT	Medicines Authority	AA032/07001, AA032/07002
SG	Health Sciences Authority	00664P